Note: Ingredients listed on restricted chemical lists
EC/CAS
215-185-5/1310-73-2
Name of the chemical
sodium hydroxide
Concentration
>=0.4-< 0.5%
General Information
Version
8.5
Revision date
2024-07-02
Product name
Sodium hydroxide solution 0,1 mol/L
CAS No.
1310-73-2
REACH No
This
1.2.1 Relevant identified uses
Pharmaceutical production
Emergency telephone
+44 (0)870 8200418
Icons in SDS
Company Information
company name
Merck Life Science UK Limited
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H290, H318
Hazard statements
Code
Statements
H290
May be corrosive to metals
Section 2
SECTION 2: Hazards identification
2.2 Label elements
Labelling
Signal word
Danger Danger
Hazard statements
H290 May be corrosive to metals. H318 Causes serious eye damage. Reduced Labeling (<= 125 ml) H318 Causes serious eye damage.
Precautionary statements
P234 Keep only in original packaging. P280 Wear eye protection/ face protection. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P390 Absorb spillage to prevent material damage. P280 Wear eye protection/ face protection. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
